The DOI matches its Crossref record; 276 of the 276 references it cites were found in a registry or an index.
Sphingolipids, Insulin Resistance, and Metabolic Disease: New Insights from in Vivo Manipulation of Sphingolipid Metabolism
Open accessAbstract
Obesity and dyslipidemia are risk factors for metabolic disorders including diabetes and cardiovascular disease.Sphingolipids such as ceramide and glucosylceramides, while being a relatively minor component of the lipid milieu in most tissues, may be among the most pathogenic lipids in the onset of the sequelae associated with excess adiposity.Circulating factors associated with obesity (e.g., saturated fatty acids, inflammatory cytokines) selectively induce enzymes that promote sphingolipid synthesis, and lipidomic profiling reveals relationships between tissue sphingolipid levels and certain metabolic diseases.Moreover, studies in cultured cells and isolated tissues implicate sphingolipids in certain cellular events associated with diabetes and cardiovascular disease, including insulin resistance, pancreatic -cell failure, cardiomyopathy, and vascular dysfunction.However, definitive evidence that sphingolipids contribute to insulin resistance, diabetes, and atherosclerosis has come only recently, as researchers have found that pharmacological inhibition or genetic ablation of enzymes controlling sphingolipid synthesis in rodents ameliorates each of these conditions.Herein we will review the role of ceramide and other sphingolipid metabolites in insulin resistance, -cell failure, cardiomyopathy, and vascular dysfunction, focusing on these in vivo studies that identify enzymes controlling sphingolipid metabolism as therapeutic targets for combating metabolic disease.(Endocrine Reviews 29: 381-402, 2008) I. Introduction II.Regulation of Sphingolipid Synthesis and Metabolism: Effect of Obesity A. Sphingolipids in the diet B. Regulation of sphingolipid synthesis and metabolism during obesity C. Quantification of sphingolipid levels during obesity III.Sphingolipids in Atherosclerosis A. Modulation of sphingolipid levels prevents plaque formation in ApoE-deficient mice B. Mechanism by which sphingolipids promote atherosclerosis and thrombosis IV.Sphingolipids in Insulin Resistance A. Modulating sphingolipid levels impacts insulin sensitivity in vivo B. Mechanism by which sphingolipids antagonize insulin action V. Sphingolipids in Pancreatic -Cell Failure A. Modulating sphingolipid levels impacts the -cell in rodent models of diabetes B. Mechanism of ceramide-mediated -cell failure C. Mechanism of glucoslyceramide-mediated -cell failure D. S1P as a regulator of -cell growth and survival VI.Sphingolipids in Cardiomyopathy A. Modulating sphingolipid levels ameliorates cardiac dysfunction in a rodent model of lipotoxic cardiomyopathy B. Mechanism by which ceramides promote cardiomyocyte dysfunction and apoptosis VII.Conclusions and Considerations
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Dan, H. C., Sun, M., Yang, L., Feldman, R. I., Sui, X.-M., Ou, C. C., Nellist, M., Yeung, R. S., Halley, D. J. J., Nicosia, S. V., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m205838200 · Cited by 370
RetractedRole of Insulin Resistance in Human Disease
Reaven, G. M. (1988) · Diabetes · doi:10.2337/diab.37.12.1595 · Cited by 12,154
Prevalence of Overweight and Obesity in the United States, 1999-2004
Ogden, C. L., Carroll, M. D., Curtin, L. R., McDowell, M. A., Tabak, C. J., & Flegal, K. M. (2006) · JAMA · doi:10.1001/jama.295.13.1549 · Cited by 8,720
Central nervous system control of food intake
Schwartz, M. W., Woods, S. C., Porte, D., Seeley, R. J., & Baskin, D. G. (2000) · Nature · doi:10.1038/35007534 · Cited by 6,451
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex
Sarbassov, D. D., Guertin, D. A., Ali, S. M., & Sabatini, D. M. (2005) · Science · doi:10.1126/science.1106148 · Cited by 6,216
Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B
Cross, D. A. E., Alessi, D. R., Cohen, P., Andjelkovich, M., & Hemmings, B. A. (1995) · Nature · doi:10.1038/378785a0 · Cited by 5,244
Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
Nissen, S. E., & Wolski, K. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072761 · Cited by 4,675 · cited 1×
“These observations are interesting because TZDs have come under recent scrutiny over concerns that they may increase cardiac complications in diabetics (167, 168).”
BackgroundInflammation, stress, and diabetes
Wellen, K. E., & Hotamisligil, G. S. (2005) · Journal of Clinical Investigation · doi:10.1172/jci25102 · Cited by 4,143
TLR4 links innate immunity and fatty acid-induced insulin resistance
Shi, H., Kokoeva, M. V., Inouye, K., Tzameli, I., Yin, H., & Flier, J. S. (2006) · Journal of Clinical Investigation · doi:10.1172/jci28898 · Cited by 3,690
A Potential Decline in Life Expectancy in the United States in the 21st Century
Olshansky, S. J., Passaro, D. J., Hershow, R. C., Layden, J., Carnes, B. A., Brody, J., Hayflick, L., Butler, R. N., Allison, D. B., & Ludwig, D. S. (2005) · New England Journal of Medicine · doi:10.1056/nejmsr043743 · Cited by 2,612
Cited by
Mechanisms of Insulin Action and Insulin Resistance
Petersen, M. C., & Shulman, G. I. (2018) · Physiological Reviews · doi:10.1152/physrev.00063.2017 · Cited by 3,028
Incalza, M. A., D'Oria, R., Natalicchio, A., Perrini, S., Laviola, L., & Giorgino, F. (2018) · Vascular Pharmacology · doi:10.1016/j.vph.2017.05.005 · Cited by 1,356
Anderson, E. J., Lustig, M. E., Boyle, K. E., Woodlief, T. L., Kane, D. A., Lin, C.-T., Price, J. W., Kang, L., Rabinovitch, P. S., Szeto, H. H., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci37048 · Cited by 1,253
Metabolic Flexibility in Health and Disease
Goodpaster, B. H., & Sparks, L. M. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.04.015 · Cited by 995
Receptor-mediated activation of ceramidase activity initiates the pleiotropic actions of adiponectin
Holland, W. L., Miller, R. A., Wang, Z. V., Sun, K., Barth, B. M., Bui, H. H., Davis, K. E., Bikman, B. T., Halberg, N., Rutkowski, J. M., et al. (2011) · Nature Medicine · doi:10.1038/nm.2277 · Cited by 892
“Ceramide and its glycerol-based counterpart, diacylglycerol (DAG), correlate with impaired insulin action in muscl”
BackgroundSelf-citationMetabolic Syndrome and Insulin Resistance: Underlying Causes and Modification by Exercise Training
Roberts, C. K., Hevener, A. L., & Barnard, R. J. (2013) · Comprehensive Physiology · doi:10.1002/cphy.c110062 · Cited by 831
Turpin, S. M., Nicholls, H. T., Willmes, D. M., Mourier, A., Brodesser, S., Wunderlich, C. M., Mauer, J., Xu, E., Hammerschmidt, P., Brönneke, H. S., et al. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.08.002 · Cited by 691
Targeting adipose tissue in the treatment of obesity-associated diabetes
Kusminski, C. M., Bickel, P. E., & Scherer, P. E. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.75 · Cited by 678
Haus, J. M., Kashyap, S. R., Kasumov, T., Zhang, R., Kelly, K. R., DeFronzo, R. A., & Kirwan, J. P. (2009) · Diabetes · doi:10.2337/db08-1228 · Cited by 663
Adiponectin regulation and function
Fang, H., & Judd, R. L. (2018) · Comprehensive physiology · doi:10.1002/cphy.c170046 · Cited by 631
A Ceramide-Centric View of Insulin Resistance
Chavez, J. A., & Summers, S. A. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.04.002 · Cited by 610
Self-citationCellular mechanism of insulin resistance in nonalcoholic fatty liver disease
Kumashiro, N., Erion, D. M., Zhang, D., Kahn, M., Beddow, S. A., Chu, X., Still, C. D., Gerhard, G. S., Han, X., Dziura, J., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1113359108 · Cited by 585
The cell biology of fat expansion
Rutkowski, J. M., Stern, J. H., & Scherer, P. E. (2015) · Journal of Cell Biology · doi:10.1083/jcb.201409063 · Cited by 541
Hannun, Y. A., & Obeid, L. M. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.r111.254359 · Cited by 541
Obesity, Bioactive Lipids, and Adipose Tissue Inflammation in Insulin Resistance
Kojta, I., Chacińska, M., & Błachnio-Zabielska, A. (2020) · Nutrients · doi:10.3390/nu12051305 · Cited by 526
Brain metabolic dysfunction at the core of Alzheimer's disease
de la Monte, S. M., & Tong, M. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.12.012 · Cited by 461
Brain Insulin Resistance and Deficiency as Therapeutic Targets in Alzheimers Disease
M. de la Monte, S. (2012) · Current Alzheimer Research · doi:10.2174/156720512799015037 · Cited by 448
Sphingolipids and phospholipids in insulin resistance and related metabolic disorders
Meikle, P. J., & Summers, S. A. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.169 · Cited by 423
Self-citationCeramides as modulators of cellular and whole-body metabolism
Bikman, B. T., & Summers, S. A. (2011) · Journal of Clinical Investigation · doi:10.1172/jci57144 · Cited by 419
Self-citationInsulin resistance and Alzheimer's disease
De La Monte, S. M. (2009) · BMB Reports · doi:10.5483/bmbrep.2009.42.8.475 · Cited by 392
“which further impair insulin signaling, mitochondrial function, and cell viability (54).”
BackgroundDiscovery of Sexual Dimorphisms in Metabolic and Genetic Biomarkers
Mittelstrass, K., Ried, J. S., Yu, Z., Krumsiek, J., Gieger, C., Prehn, C., Roemisch-Margl, W., Polonikov, A., Peters, A., Theis, F. J., et al. (2011) · PLoS Genetics · doi:10.1371/journal.pgen.1002215 · Cited by 383
Plasma lipid profiling in a large population-based cohort
Weir, J. M., Wong, G., Barlow, C. K., Greeve, M. A., Kowalczyk, A., Almasy, L., Comuzzie, A. G., Mahaney, M. C., Jowett, J. B. M., Shaw, J., et al. (2013) · Journal of Lipid Research · doi:10.1194/jlr.p035808 · Cited by 366
The Spectrum of Fungi That Infects Humans
Kohler, J. R., Casadevall, A., & Perfect, J. (2015) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a019273 · Cited by 364
Bioactive lipids, inflammation and chronic diseases
Leuti, A., Fazio, D., Fava, M., Piccoli, A., Oddi, S., & Maccarrone, M. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.06.028 · Cited by 358
Metabolic-cognitive syndrome: A cross-talk between metabolic syndrome and Alzheimer's disease
Frisardi, V., Solfrizzi, V., Seripa, D., Capurso, C., Santamato, A., Sancarlo, D., Vendemiale, G., Pilotto, A., & Panza, F. (2010) · Ageing Research Reviews · doi:10.1016/j.arr.2010.04.007 · Cited by 357
Paracrine and Endocrine Effects of Adipose Tissue on Cancer Development and Progression
Park, J., Euhus, D. M., & Scherer, P. E. (2011) · Endocrine Reviews · doi:10.1210/er.2010-0030 · Cited by 348
Metabolic Messengers: adiponectin
Straub, L. G., & Scherer, P. E. (2019) · Nature Metabolism · doi:10.1038/s42255-019-0041-z · Cited by 347
Lipid-Induced Mitochondrial Stress and Insulin Action in Muscle
Muoio, D. M., & Neufer, P. D. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.04.010 · Cited by 343
Metabolomics Applied to Diabetes Research
Bain, J. R., Stevens, R. D., Wenner, B. R., Ilkayeva, O., Muoio, D. M., & Newgard, C. B. (2009) · Diabetes · doi:10.2337/db09-0580 · Cited by 328
Wang, D. D., Toledo, E., Hruby, A., Rosner, B. A., Willett, W. C., Sun, Q., Razquin, C., Zheng, Y., Ruiz-Canela, M., Guasch-Ferré, M., et al. (2017) · Circulation · doi:10.1161/circulationaha.116.024261 · Cited by 327
“In the present study based on the PREDIMED trial, we hypothesized that (1) plasma ceramide concentrations at baseline were associated with incident clinical events of CVD, (2) the association between baseline plasma ceramide concentrations and incident CVD was modified by the MedDiet interventions, and (3) participant…”
MethodDiabetes and apoptosis: lipotoxicity
Kusminski, C. M., Shetty, S., Orci, L., Unger, R. H., & Scherer, P. E. (2009) · Apoptosis · doi:10.1007/s10495-009-0352-8 · Cited by 302
Role of ceramides in nonalcoholic fatty liver disease
Pagadala, M., Kasumov, T., McCullough, A. J., Zein, N. N., & Kirwan, J. P. (2012) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2012.04.005 · Cited by 303
Boon, J., Hoy, A. J., Stark, R., Brown, R. D., Meex, R. C., Henstridge, D. C., Schenk, S., Meikle, P. J., Horowitz, J. F., Kingwell, B. A., et al. (2013) · Diabetes · doi:10.2337/db12-0686 · Cited by 303
The Role of Ceramides in Insulin Resistance
Sokolowska, E., & Blachnio-Zabielska, A. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00577 · Cited by 297
Martins, A. R., Nachbar, R. T., Gorjao, R., Vinolo, M. A., Festuccia, W. T., Lambertucci, R. H., Cury-Boaventura, M. F., Silveira, L. R., Curi, R., & Hirabara, S. M. (2012) · Lipids in Health and Disease · doi:10.1186/1476-511x-11-30 · Cited by 290
Glycosphingolipids—Nature, Function, and Pharmacological Modulation
Wennekes, T., van den Berg, R. J. B. H. N., Boot, R. G., van der Marel, G. A., Overkleeft, H. S., & Aerts, J. M. F. G. (2009) · Angewandte Chemie International Edition · doi:10.1002/anie.200902620 · Cited by 288
Metabolomics in the study of kidney diseases
Weiss, R. H., & Kim, K. (2012) · Nature Reviews Nephrology · doi:10.1038/nrneph.2011.152 · Cited by 264
Adiponectin, driver or passenger on the road to insulin sensitivity?
Ye, R., & Scherer, P. E. (2013) · Molecular Metabolism · doi:10.1016/j.molmet.2013.04.001 · Cited by 251
Leroux, A., Ferrere, G., Godie, V., Cailleux, F., Renoud, M.-L., Gaudin, F., Naveau, S., Prévot, S., Makhzami, S., Perlemuter, G., et al. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.02.028 · Cited by 246
Watt, M. J., & Hoy, A. J. (2012) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00561.2011 · Cited by 142
Scherer, P. E. (2016) · Diabetes · doi:10.2337/db16-0339 · Cited by 133
“The connection between adiponectin and lipid metabolism is particularly apparent when we look at the broad category of lipids referred to as ceramides (55).”
Sphingolipids and insulin resistance: the five Ws
Summers, S. A. (2010) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e3283373b66 · Cited by 136
Self-citationMechanisms of Lipotoxicity in the Cardiovascular System
Wende, A. R., Symons, J. D., & Abel, E. D. (2012) · Current Hypertension Reports · doi:10.1007/s11906-012-0307-2 · Cited by 110
Kitessa, S., & Abeywardena, M. (2016) · Nutrients · doi:10.3390/nu8080466 · Cited by 98
Promrat, K., Longato, L., Wands, J. R., & de la Monte, S. M. (2011) · Hepatology Research · doi:10.1111/j.1872-034x.2011.00815.x · Cited by 66
Franko, A., von Kleist-Retzow, J. C., Böse, M., Sanchez-Lasheras, C., Brodesser, S., Krut, O., Kunz, W. S., Wiedermann, D., Hoehn, M., Stöhr, O., et al. (2012) · Journal of Molecular Medicine · doi:10.1007/s00109-012-0887-y · Cited by 39
“These metabolites are thought to be responsible for alterations in the phosphorylation state of proteins involved in signaling pathways from the insulin receptor (InsR) to the glucose uptake machinery [2, 3].”
BackgroundInfluentialLaeger, T., Castaño-Martinez, T., Werno, M. W., Japtok, L., Baumeier, C., Jonas, W., Kleuser, B., & Schürmann, A. (2018) · Diabetologia · doi:10.1007/s00125-018-4595-1 · Cited by 17
Chung, J. O., Koutsari, C., Blachnio-Zablieska, A. U., Hames, K. C., & Jensen, M. D. (2018) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00153.2017 · Cited by 8
“Because the serine palmitoyltransferase, the rate-limiting enzyme in de novo ceramide synthesis, is largely influenced by substrate availability (17), increased FFA availability might contribute to increased concentrations of intramyocellular ceramides in obesity.”
Background
Metadata
- Authors
- Holland, W. L., & Summers, S. A.
- Venue
- Endocrine Reviews
- Publisher
- The Endocrine Society
- Published
- 2008-05-01
- Volume
- 29
- Issue
- 4
- Pages
- 381-402
- ISSN
- 0163-769X (ISSN-L)
- 1945-7189
- OpenAlex
- W2164509237
- Cited by
- 595
- References
- 276
- FWCI
- 12.04
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.